Affordable Access

deepdyve-link
Publisher Website

Subconjunctival injection of XG-102, a JNK inhibitor peptide, in patients with intraocular inflammation: a safety and tolerability study.

Authors
  • Beydoun, Talal
  • Deloche, Catherine
  • Perino, Julien
  • Kirwan, Bridget-Anne
  • Combette, Jean-Marc
  • Behar-Cohen, Francine
Type
Published Article
Journal
Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics
Publication Date
Mar 01, 2015
Volume
31
Issue
2
Pages
93–99
Identifiers
DOI: 10.1089/jop.2013.0247
PMID: 25347151
Source
Medline
License
Unknown

Abstract

In this first clinical trial using XG-102, administered as a single subconjunctival injection as adjunct therapy, in patients with recent post-surgery or post-trauma intraocular inflammation is safe and well tolerated. Further studies are required to evaluate its efficacy.

Report this publication

Statistics

Seen <100 times